GlaukosGKOS
Market Cap: $7.1B
About: Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Employees: 907
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
150% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 5 (+3) [Q2]
115% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 27
34% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 80
31% more capital invested
Capital invested by funds: $4.89B [Q1] → $6.4B (+$1.5B) [Q2]
12% more funds holding
Funds holding: 252 [Q1] → 283 (+31) [Q2]
2.37% more ownership
Funds ownership: 104.93% [Q1] → 107.3% (+2.37%) [Q2]
44% less call options, than puts
Call options by funds: $9.55M | Put options by funds: $17.2M
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
10 analyst ratings
Stifel Thomas Stephan 63% 1-year accuracy 12 / 19 met price target | 12%upside $145 | Buy Maintained | 3 Sept 2024 |
BTIG Ryan Zimmerman 56% 1-year accuracy 19 / 34 met price target | 8%upside $139 | Buy Maintained | 28 Aug 2024 |
Piper Sandler Matt O'Brien 50% 1-year accuracy 22 / 44 met price target | 8%upside $140 | Overweight Maintained | 1 Aug 2024 |
Wells Fargo Larry Biegelsen 68% 1-year accuracy 25 / 37 met price target | 4%upside $135 | Overweight Maintained | 1 Aug 2024 |
Truist Securities Richard Newitter 67% 1-year accuracy 29 / 43 met price target | 12%upside $145 | Buy Reiterated | 1 Aug 2024 |